drugset / Trial / NCT00661544
Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
NaSingle-groupOpen-labelTreatment
Summary
1. To evaluate the toxicity and safety of a combination of arsenic trioxide with ascorbic acid and high-dose Melphalan in patients with multiple myeloma 2. To evaluate the efficacy of a combination of arsenic trioxide with ascorbic acid and high-dose Melphalan in patients with multiple myeloma 3. To determine the effects of arsenic trioxide on melphalan pharmacokinetics
Timeline
- Start
- 2004-03
- Primary completion
- 2007-06
- Completion
- 2007-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Melphalan | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Vitamin C | Other / unclassified | 1000 mg | Intravenous |
| Subject | arsenic trioxide | Small molecule | 0.15 mg/kg | Intravenous |
| Subject | arsenic trioxide | Small molecule | 0.25 mg/kg | Intravenous |